Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Asset Writedowns and Impairment: 2018-2020

Historic Asset Writedowns and Impairment for Outlook Therapeutics (OTLK) over the last 1 years, with Jun 2020 value amounting to $104,296.

  • Outlook Therapeutics' Asset Writedowns and Impairment rose 104.80% to $104,296 in Q2 2020 from the same period last year, while for Jun 2020 it was $9.1 million, marking a year-over-year change of. This contributed to the annual value of $527,624 for FY2020, which is 95.33% down from last year.
  • Per Outlook Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $104,296 for Q2 2020, which was down 98.75% from $8.3 million recorded in Q3 2019.
  • Outlook Therapeutics' Asset Writedowns and Impairment's 5-year high stood at $8.3 million during Q3 2019, with a 5-year trough of $50,927 in Q2 2019.
  • Over the past 3 years, Outlook Therapeutics' median Asset Writedowns and Impairment value was $561,735 (recorded in 2019), while the average stood at $2.3 million.
  • Data for Outlook Therapeutics' Asset Writedowns and Impairment shows a peak YoY skyrocketed of 104.80% (in 2020) over the last 5 years.
  • Outlook Therapeutics' Asset Writedowns and Impairment (Quarterly) stood at $2.3 million in 2018, then reached $8.3 million in 2019, then surged by 104.80% to $104,296 in 2020.
  • Its Asset Writedowns and Impairment stands at $104,296 for Q2 2020, versus $8.3 million for Q3 2019 and $50,927 for Q2 2019.